semaglutide compounding fda enforcement news today alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products FDA Crackdown on Compounded GLP-1

GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2

Instead of asking how high the dose can go, the question becomes: Whats the lowest dose that still delivers benefits

Real change

Statistical significance was set at P 50%

That is why current research focuses on improved delivery systems

To be a candidate for a weight loss peptide, namely a GLP-1 RA, you typically need to meet one or several of the following diagnostic criteria: Obesity: Obesity is defined as having a body mass index (BMI) above 30 (e.g., someone whos 511 and weighs 215lb would qualify as obese),22 but a BMI slightly below 30 doesnt disqualify you for a peptide prescription